-
Product Insights
Peritoneal Tumor - Drugs In Development, 2024
Empower your strategies with our Peritoneal Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Peritoneal tumor is the invasion of the serous membrane lining the peritoneal cavity by malignant cells, that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. The malignant cells originate de novo in the mesothelioma or disseminate from other primary tumor sites. The Peritoneal Tumor drugs in development market research report provide comprehensive...
-
Product Insights
Recurrent Malignant Glioma - Drugs In Development, 2024
Empower your strategies with our Recurrent Malignant Glioma  – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent malignant glioma is defined as the recurrence of a glioma tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back,...
-
Product Insights
Secondary Acute Myeloid Leukemia - Drugs In Development, 2024
Empower your strategies with our Secondary Acute Myeloid Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. Secondary acute myeloid leukemia includes acute myeloid leukemia that arises either from a previous myeloid hematologic disease such as myelodysplastic syndrome, chronic myeloproliferative syndrome, or myelodysplastic/myeloproliferative overlap syndromes or from a previous chemotherapy or radiotherapy performed for another disease The Secondary Acute Myeloid Leukemia drugs in development market research report provide comprehensive information on the therapeutics under development for Secondary...
-
Product Insights
Acral Lentiginous Melanoma - Drugs In Development, 2024
Empower your strategies with our Acral Lentiginous Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Acral lentiginous melanoma (ALM), also sometimes referred to as, simply, acral melanoma, is melanoma occurring on the hands and feet (palms, soles, fingers, toes, and nail units). This is is a subtype of cutaneous malignant melanoma. The condition can develop in normal-appearing skin or within an existing mole. It is comprised of malignant melanocytes, which can become invasive with time. The...
-
Product Insights
Cutaneous Angiosarcoma - Drugs In Development, 2024
Empower your strategies with our Cutaneous Angiosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Cutaneous angiosarcoma (cAS) is a rare and aggressive subtype of soft tissue sarcoma with poor prognosis and suboptimal treatment options. The Cutaneous Angiosarcoma drugs in development market research report provide comprehensive information on the therapeutics under development for Cutaneous Angiosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report...
-
Product Insights
Ductal Carcinoma In Situ - Drugs In Development, 2024
Empower your strategies with our Ductal Carcinoma In Situ – Drugs In Development, 2024 report and make more profitable business decisions. Ductal carcinoma in situ (DCIS), also referred to as intraductal carcinoma, is a non-invasive breast cancer characterized by a proliferation of abnormal epithelial cells confined within the basement membrane. Disruption of the basement membrane layer would change the diagnosis from DCIS to invasive breast cancer. DCIS is considered to be a precursor for invasive breast cancer. The Ductal Carcinoma In...
-
Product Insights
Next Generation Sequencing (NGS) Tests Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Next Generation Sequencing (NGS) Tests Pipeline Market Overview Next generation sequencing (NGS) refers to high-throughput methods for DNA sequencing that are not Sanger-based. NGS technology has largely superseded Sanger sequencing in academic or genome research and is increasingly being applied in clinical practice. Key Territories ·       The US ·       China ·       Global ·       Europe ·       South Korea Key Regulatory Paths ·       510(k) ·       NMPA ·       PMA ·       CE-IVD ·       CLIA Leading Companies ·       4bases SA ·       AccuraGen Inc ·       ACT...
-
Sector Analysis
HER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
Reasons to buy the ‘HER2-Positive Breast Cancer Epidemiology’ market report: Get an overview of the HER2+ breast cancer risk factors, comorbidities, and global and historical epidemiological trends in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). Get valuable insights into the 10-year epidemiology forecast for Diagnosed incident cases of all invasive breast cancer Diagnosed incident cases of HER2+ breast cancer Five diagnosed prevalent cases of HER2+ breast cancer Understand the diagnosed incident cases...
-
Product Insights
Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
HER2 Negative Breast Cancer Clinical Trial Analysis Report Overview A total of 2,230 HER2- breast cancer clinical trials were conducted as of February 2024. The following are some of the key highlights of the HER2 breast cancer clinical trial report: As of February 2024, North America led the HER2- breast cancer clinical trials landscape with more than 32% of the clinical trials conducted there. In 2024, Pfizer conducted the highest number of HER2- breast cancer clinical trials. The HER2- breast...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) Epidemiology Analysis and Forecast to 2032
Non-Small Cell Lung Cancer (NSCLC) Report Overview In the 8MM, there were 1,097,467 diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) in 2022. The diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) will register an AGR of more than 2% during 2022-2032. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, NSCLC can begin anywhere in the lungs when the healthy cells that make up the lining of the lungs change and grow out...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.